Trial Profile

A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients With Recurrent Glioblastoma

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NMS 293 (Primary) ; Temozolomide (Primary) ; Lomustine
Indications Astrocytoma; Glioblastoma; Oligodendroglioma
Focus Adverse reactions; Therapeutic Use
Sponsors Nerviano Medical Sciences

Most Recent Events

03 Apr 2025 Status changed from recruiting to active, no longer recruiting.
31 Jan 2025 According to a Nerviano Medical Sciences media release, company has presented preclinical features and preliminary clinical data of the highly unique non-trapping, PARP1 selective inhibitor NMS-293 under topic 'Exploring Next-Gen PARP Inhibitors without PARP Trapping' at the recent 8th Annual DDR Inhibitors Summit.
13 Mar 2024 Planned number of patients changed from 125 to 150.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com